183
and dasabuvir with HIV protease inhibitors [Abstract]. Proceedings of the 54th
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC);
September 5-9, 2014;Washington, DC. Abstract V-484.
42.
Khatri A, Wang T, Wang H, Podsadecki T, Trinh R, Awni W, et al.Drug–drug
interactions of the direct-acting antiviral regimen of ABT-450/r, ombitasvir, and
dasabuvir with emtricabine1tenofovir, raltegravir,rilpivirine, and efavirenz [Abstract].
Proceedings of the 54th Interscience Conference on Antimicrobial Agents and
Chemotherapy(ICAAC); September 5-9, 2014; Washington, DC. Abstract V-483.
43.
Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, et al. Virologic
response following combined ledipasvir and sofosbuvir administration in patients
with HCV genotype 1 and HIV coinfection.JAMA 2015;31:1232-1239.
44.
Naggie S, Cooper C, Saag M, Yang J, Stamm L, Pang PS, et al. Ledipasvir/
sofosbuvir for 12 weeks in patients coinfected with HCVand HIV-1 [Abstract].
Proceedings of the Conference on Retroviruses and OpportunisticInfections;
February 23-26, 2015; Seattle, WA. Abstract 152LB.
45.
Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C,et al. Sofosbuvir
plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV
(PHOTON-2): a multicentre, openlabel, non-randomised, phase 3 study. Lancet
2015;385:1098-1106.
46.
Potthoff A, Berg T, Wedemeyer H. Late hepatitis B virus relapse in patients co-
infected with hepatitis B virus and hepatitis C virus after antiviral treatment with
pegylated interferon-a2b and ribavirin. Scand JGastroenterol 2009;44:1487–1490.
47.
McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A,
et al. Asian Pacific Association for the Study of the Liver consensus statements
on the diagnosis, management and treatment of hepatitis C virus infection. J
GastroenterolHepatol 2007;22:615–633
48.
Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity
associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of
hepatitis C and B infections. Hepatology. 2002;35:182–189.
49.
Nunez M. Clinical syndromes and consequences of antiretroviral-related
hepatotoxicity. Hepatology. 2010;52(3):1143–55.
50.
Van Wagner LB, Baker T, Ahya SN, Norvell JP, Wang E, Levitsky J. Outcomes of
patients with hepatitis C undergoing simultaneous liver-kidney transplantation.J
Hepatol 2009;51:874–880.
51.
Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, et al. International
guidelines for the selection of lung transplant candidates: 2006 update-a
consensus report from the Pulmonary Scientific Council of the International Society
for Heart and Lung Transplantation. J Heart Lung Transplant 2006;25:745–755.
52.
Darke S, Kaye S, Duflou J. Comparative cardiac pathology among deaths due
to cocaine toxicity, opioid toxicity and non-drug-related causes. Addiction
2006;101:1771–1777.
53.
Grebely J, Raffa JD, Lai C, Kerr T, Fischer B, Krajden M, et al. Impact of hepatitis C
virus infection on all-cause and liver-related mortality in a large community-based
cohort of inner city residents. J Viral Hepat 2011;18:32–41.
54.
Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of
hepatitis C virus infection in relation to time since onset of illicit drug injection: the
influence of time and place. Am J Epidemiol 2008;168:1099–1109.
55.
Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global
epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of
Özel Hasta Gruplarýnda HCV Enfeksiyonunun Tedavisi
